Introduction: We sought to examine the utility of self-reported pain scale by comparing emergency department (ED) triage pain scores of self-reported but non-verifiable painful conditions with those of verifiable painful conditions using a large, nationally representative sample.
Methods: We analyzed the National Hospital Ambulatory Medical Care Survey (NHAMCS) 2015. Verifiable painful conditions were identified based on the final diagnoses in the five included International Classification of Diseases 9th revision codes. Non-verifiable painful conditions were identified by the five main reasons for visit. Only adults 18 years of age or older were included. The primary outcome variable was the pain scale from 0 to 10 at triage. We performed descriptive and multivariate analyses to investigate the relationships between the pain scale and whether the painful condition was verifiable, controlling for patient characteristics.
Results: There were 55 million pain-related adult ED visits in 2015. The average pain scale was 6.49. For verifiable painful diagnoses, which were about 24% of the total visits, the average was 6.27, statistically significantly lower than that for non-verifiable painful conditions, 6.56. Even after controlling for the confounding of patient characteristics and comorbidities, verifiable painful diagnoses still presented less pain than those with non-verifiable painful complaints. Older age, female gender, and urban residents had significantly higher pain scores than their respective counterparts, controlling for other confounding factors. Psychiatric disorders were independently associated with higher pain scores by about a half point.
Conclusion: Self-reported pain scales obtained at ED triage likely have a larger psychological component than a physiological one. Close attention to clinical appropriateness and overall patient comfort are more likely to lead to better health outcomes and patient experiences than focusing on self-reported pain alone.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972390 | PMC |
http://dx.doi.org/10.5811/westjem.2020.11.49030 | DOI Listing |
Acta Dermatovenerol Croat
November 2024
Constantin A. Dasanu MD, PhD, Lucy Curci Cancer Center, Eisenhower Health, 39000 Bob Hope Dr, Rancho Mirage, CA 92270 , USA;
Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is currently used in the therapy of several solid malignancies. This agent has been associated with several dermatological side-effects, the most common being papulo-pustular acneiform rash. Herein we describe a unique skin effect in a patient treated with erlotinib for non-small cell lung cancer.
View Article and Find Full Text PDFKnee osteoarthritis (KOA) is a healthcare burden affecting over 595 million people worldwide. Recently, intra-articular platelet-rich plasma (PRP) injections from the patient's blood have shown promise in slowing KOA progression due to platelets' regenerative properties. This study aimed to evaluate the optimal dosing and schedule for PRP therapy in managing mild to moderate KOA.
View Article and Find Full Text PDFJ Lasers Med Sci
December 2024
Department of Periodontics, Dental Implants Research Center, Dental Research Institute, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran.
Gingival depigmentation with the help of lasers is known as an effective technique. The aim of this study was to compare the efficiency of 980nm diode and CO2 lasers in the treatment of gingival hyperpigmentation. In this clinical trial study, 14 individuals (8 females and 6 males) with the age range of 19 to 47 years were selected.
View Article and Find Full Text PDFAcute coronary syndrome (ACS) is an acute heart disease that often evolves rapidly. In ACS patients presenting with no-ST-segment elevation (NSTE-ACS), the timing of symptom onset pre-hospital may inform the disease stage and prognosis. We pilot-tested two off-the-shelf natural language processing (NLP) pipelines, namely and ( ), to extract date and time (DateTime) information of patient-reported chest pain symptoms from electronic health records (EHR) clinical notes.
View Article and Find Full Text PDFDrug Healthc Patient Saf
January 2025
Department of Pharmacy Administration, University of Mississippi School of Pharmacy, University, MS, 38677 USA.
Objective: This review summarized the real-world effectiveness outcomes of Janus kinase inhibitors (JAKi) for rheumatoid arthritis (RA) based on observational studies.
Methods: A systematic review followed PRISMA guidelines, with searches conducted in PubMed, Embase, and CINAHL from each database's inception to June 2, 2023. Studies were included if they evaluated real-world effectiveness outcomes of JAKi for US RA patients.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!